Loading organizations...
§ Private Profile · Suresnes, Ile-de-France, France
Phagos is a technology company.
Phagos develops AI-powered bacteriophage (phage) therapies, a sustainable alternative to antibiotics. Its Alphagos platform integrates advanced microbiology and artificial intelligence to design ultra-targeted bacterial treatments. This approach leverages phages' natural ability to selectively eliminate harmful bacteria, directly addressing antimicrobial resistance.
Founded in 2021 by Adèle James and Alexandros Pantalis, Phagos arose from the critical need for novel solutions against antibiotic-resistant infections. Their insight was to modernize phage technology, using bacteria's natural predators, by applying AI-driven precision to overcome prior therapeutic limitations.
Phagos currently focuses solutions on the animal farming sector, providing tailored treatments for diverse livestock. The company's vision is to establish a new paradigm in infectious disease management, delivering adaptable, precise therapies to protect global health from escalating bacterial threats.
Phagos has raised $31.0M across 2 funding rounds.
Phagos has raised $31.0M in total across 2 funding rounds.
Phagos has raised $31.0M across 2 funding rounds. Most recently, it raised $29.0M Series A in October 2025.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Oct 1, 2025 | $29M Series A | Hoxton Ventures, Anne Valérie Bach, CapHorn Invest, Demeter | Grant Aarons, ALL Iron Ventures, Citizen Capital, Entrepreneur First, Founders Capital, STATION F | Announced |
| Sep 1, 2022 | $2M Seed | — | Hoxton Ventures | Announced |
Phagos is a biotech startup founded in 2021 that develops personalized bacteriophage (phage) therapies as a sustainable alternative to antibiotics, targeting bacterial infections in animal health with ambitions to expand to humans[1][2][4]. The company serves livestock sectors like chicken, cattle, swine, and shrimp, solving antimicrobial resistance (AMR) by using AI-powered platforms to design ultra-precise treatments that evolve with bacterial mutations, delivering therapies in two months without harming beneficial microbes[1][2][4]. Phagos achieved a world-first regulatory approval for personalized veterinary phage drugs and raised €25M in Series A funding in 2024 to scale globally, marking strong growth momentum with field deployments across three continents and recognition on the FoodTech 500 list[1][2].
Phagos was co-founded in 2021 by CEO Alexandros Pantalis, an entrepreneur, and microbiologist Adèle James, who holds a PhD in phage ecology and was initially drawn to phages through research rather than business plans[2]. The idea emerged from their discussions on phage applications, starting with industrial uses like bacterial contamination in paper factories and ship biofilms, before pivoting to animal health for its immediate impact amid rising antibiotic limitations[2]. Early traction came via a groundbreaking regulatory milestone as the first company authorized to market personalized phage-based veterinary drugs, coupled with a patented AI platform for phage-bacteria interaction prediction, setting the stage for rapid scaling[1].
Phagos rides the global AMR crisis, projected to cause millions of deaths, by pioneering phage therapy in a $tens-of-billions veterinary market strained by antibiotic failures[1][4]. Timing aligns with regulatory shifts favoring innovation in animal health and foodtech, as seen in its FoodTech 500 recognition and deployments with industry leaders[1][2]. Market forces like demand for sustainable livestock solutions boost it, especially in regions with flexible regulations, while its AI-driven scalability influences biotech by making phage therapy viable beyond niche cases—potentially reshaping human medicine and agriculture ecosystems[1][2].
Phagos is poised to dominate veterinary phage therapy, using its €25M funding to expand R&D, team (90% scientific), and global presence, including U.S. entry for livestock health[1][2]. Trends like AI-biotech convergence and AMR urgency will propel growth, evolving its influence from animal trials to human applications and food sector innovations. This positions Phagos to deliver on its mission of ending bacterial diseases, transforming a looming crisis into scalable, tech-driven prevention.
Phagos has raised $31.0M in total across 2 funding rounds.
Phagos's investors include Hoxton Ventures, Anne-Valérie Bach, CapHorn Invest, Demeter, Grant Aarons, All Iron Ventures, Citizen Capital, Entrepreneur First, Founders Capital, Station F.